Solventum Corporation (SOLV)
Tecnología médica y salud digital
Solventum is 3M's spin-off in medical technology (MedSurg, Dental Solutions and health information systems); its reported profit is distorted by the $1,500M gain from the sale of Purification and Filtration and by separation costs still being unwound, on a normalized operating margin that is already returning to the company's pre-disruption levels (Very undervalued, +19% annual over 5 years versus the market price).
- Price
- $91.30
- Intrinsic value (5y, base)
- $217
- Total annual return (5y)
- 18.9%
- Status (nominal)
- Very undervalued
- Margin of safety
- +48%
The essentials
- Three segments of different nature: MedSurg and Dental Solutions (regulated medical devices) and Health Information Systems (hospital revenue-cycle software) — the company itself announced on Aug-5-2026 its intent to separate Health Information Systems.
- The last year's EBIT and net income include a non-recurring gain of $1,500M from the sale of the Purification and Filtration business (Sep-2025): no reported figure from the base year should be read as recurring without normalizing.
- Meaningful debt (~$5,100M) inherited from the 2024 spin-off financing, with separation and litigation costs still depressing the GAAP operating margin well below the adjusted margin the company reports.
- Share buybacks only recently started in 2026 ($355M in the first half) — too recent and above the guided full-year free cash flow to project as sustained.
Intrinsic value — two valuation methods
By both methods, the value today (DCF $182 · Multiples $174) exceeds the market price ($91).
Pillars of the analysis
The verdict — today vs 5 years
Today — with margin of safety: at $91 trades ~47.6% below its value discounted to today (~$174) — the wide discount we require (≥38%, equivalent to a ~15% annual return); the risk is covered by the margin, not the rate.
At 5 years — Muy infravalorado: the target price ($217) plus dividends yield above the required average return (10%) — the business compounds.
The bridge: the return at 5 years comfortably exceeds the risk-free rate (4.5%) — and the discount reaches the required margin of safety.
Thesis
The business
A mid-quality medical technology company, with a narrow and eroding moat, still transitioning through its separation from 3M (2024) and a second portfolio restructuring (the 2025 sale of Purification and Filtration and the announced separation of Health Information Systems). The underlying business generates reasonable operating margins once the non-recurring transition costs are cleaned out.
The valuation
Valued by sum of the parts: MedSurg plus Dental Solutions with a medical technology multiple, and Health Information Systems with a mature software multiple, both on normalized EBIT (excluding the $1,500M gain from the Purification and Filtration sale and the separation costs already quantified by the company itself). The result is a 5-year value of $217 per share, a +19% annual return versus the market price.
The margin of safety
There is a margin of safety: the market's perception is meaningfully worse than reality. The market price does not appear to be pricing in the recovery of the operating margin toward the pre-disruption levels (2022-2023) that the company's own non-GAAP reconciliation already shows quarter after quarter.
What to watch
The central disconfirmer is whether separation and litigation costs actually unwind as the path assumes, or become structural — and whether the announced separation of Health Information Systems is executed at a price that recognizes its software multiple, or ends up being a forced sale on weak terms given the company's current leverage.
Educational / informational. Does not constitute investment advice.